• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Metsera Inc.

    10/31/25 11:05:39 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Metsera Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    59267L107

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    403,600.00
    7Sole Dispositive Power

    5,382,209.00
    8Shared Dispositive Power

    442,784.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,824,993.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.53 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Metsera Inc
    (b)Address of issuer's principal executive offices:

    3 World Trade Ctr, 175 Greenwich St, New York, NY, 10007
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    59267L107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5824993
    (b)Percent of class:

    5.53  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    403600

     (iii) Sole power to dispose or to direct the disposition of:

    5382209

     (iv) Shared power to dispose or to direct the disposition of:

    442784

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/31/2025
    Get the next $MTSR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    9/30/2025$54.00Overweight → Equal Weight
    Wells Fargo
    9/9/2025$77.00Outperform
    Leerink Partners
    6/20/2025$65.00Overweight
    Wells Fargo
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:15:35 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:04:05 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:01:33 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Metsera Issues Statement in Response to Litigation

    NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer: "Metsera disagrees with the allegations in Pfizer's complaint and will address them in the Delaware Court of Chancery."   Disclosure Notice  This release contains forward-looking information about, among other topics, Pfizer's proposed acquisition of Metsera, Pfizer's and Metsera's pipeline products, including their potential benefits, potential best-in-class status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition

    10/31/25 6:24:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

    Pfizer Inc. (NYSE:PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to Pfizer's pending acquisition of Metsera (NASDAQ:MTSR). The termination of the waiting period under the HSR Act satisfies the regulatory review requirements under the previously announced proposed acquisition of Metsera, which was set to expire on November 7. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to

    10/31/25 3:50:00 PM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Receives Unsolicited Proposal from Novo Nordisk

    Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments to Existing Transaction Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Oct. 30, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) ("Novo Nordisk") to acquire Metsera (th

    10/30/25 7:07:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    See Remark 1 Fmr Llc gifted 633,715 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    10/8/25 3:35:08 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: See Remark 1 Fmr Llc acquired 1,107,547 shares (SEC Form 4)

    4/A - Metsera, Inc. (0002040807) (Issuer)

    9/12/25 4:09:01 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See Remark 1 Fmr Llc sold $9,648 worth of shares (268 units at $36.00), disposed of 2,367,294 shares, acquired 2,151,820 shares and acquired 895 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    9/4/25 2:58:55 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Metsera Inc.

    SCHEDULE 13G - Metsera, Inc. (0002040807) (Subject)

    10/31/25 11:05:39 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Metsera Inc.

    DEFA14A - Metsera, Inc. (0002040807) (Filer)

    10/30/25 10:49:07 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Inc. filed SEC Form 8-K: Other Events

    8-K - Metsera, Inc. (0002040807) (Filer)

    10/30/25 7:39:59 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Metsera downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Metsera from Overweight to Equal Weight and set a new price target of $54.00

    9/30/25 8:33:25 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Metsera with a new price target

    Leerink Partners initiated coverage of Metsera with a rating of Outperform and set a new price target of $77.00

    9/9/25 7:59:28 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Metsera with a new price target

    Wells Fargo initiated coverage of Metsera with a rating of Overweight and set a new price target of $65.00

    6/20/25 7:54:18 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Financials

    Live finance-specific insights

    View All

    Metsera Receives Unsolicited Proposal from Novo Nordisk

    Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments to Existing Transaction Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Oct. 30, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) ("Novo Nordisk") to acquire Metsera (th

    10/30/25 7:07:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

    Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a

    9/22/25 6:45:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

    Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb

    6/9/25 7:00:00 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care